Transcription of the human immunodeficiency virus type 1 (HIV) requires the interaction of the cyclin T1 (CycT1) subunit of a host cellular factor, the positive transcription elongation factor b (P-TEFb), with the viral Tat protein, at the transactivation response element (TAR) of nascent transcripts. Because of this virus-specific interaction, CycT1 may potentially serve as a target for the development of anti-HIV therapies. Here we report the development of a mutant CycT1 protein, containing three threonine-to-alanine substitutions in the linker region between two of the cyclin boxes, which displays a potent dominant negative effect on HIV transcription. Investigation into the inhibitory mechanism revealed that this mutant CycT1 interacted with Tat and the cyclin-dependent kinase 9 (Cdk9) subunit of P-TEFb, but failed to stimulate the Cdk9 kinase activity critical for elongation. This mutant CycT1 protein may represent a novel class of specific inhibitors of HIV transcription which could lead to development of new antiviral therapies.
BarboricM.,
YikJ. H.,
CzudnochowskiN.,
YangZ.,
ChenR.,
ContrerasX.,
GeyerM.,
Matija PeterlinB.,
ZhouQ.2007; Tat competes with HEXIM1 to increase the active pool of P-TEFb for HIV-1 transcription. Nucleic Acids Res 35:2003–2012[CrossRef]
BieniaszP. D.,
GrdinaT. A.,
BogerdH. P.,
CullenB. R.1998; Recruitment of a protein complex containing Tat and cyclin T1 to TAR governs the species specificity of HIV-1 Tat. EMBO J 17:7056–7065[CrossRef]
BieniaszP. D.,
GrdinaT. A.,
BogerdH. P.,
CullenB. R.1999; Recruitment of cyclin T1/P-TEFb to an HIV type 1 long terminal repeat promoter proximal RNA target is both necessary and sufficient for full activation of transcription. Proc Natl Acad Sci U S A 96:7791–7796[CrossRef]
ChaoS. H.,
PriceD. H.2001; Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo. J Biol Chem 276:31793–31799[CrossRef]
ChaoS. H.,
FujinagaK.,
MarionJ. E.,
TaubeR.,
SausvilleE. A.,
SenderowiczA. M.,
PeterlinB. M.,
PriceD. H.2000; Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. J Biol Chem 275:28345–28348[CrossRef]
DamesS. A.,
SchonichenA.,
SchulteA.,
BarboricM.,
PeterlinB. M.,
GrzesiekS.,
GeyerM.2007; Structure of the cyclin T binding domain of Hexim1 and molecular basis for its recognition of P-TEFb. Proc Natl Acad Sci U S A 104:14312–14317[CrossRef]
DiehlJ. A.,
SherrC. J.1997; A dominant-negative cyclin D1 mutant prevents nuclear import of cyclin-dependent kinase 4 (CDK4) and its phosphorylation by CDK-activating kinase. Mol Cell Biol 17:7362–7374
FujinagaK.,
TaubeR.,
WimmerJ.,
CujecT. P.,
PeterlinB. M.1999; Interactions between human cyclin T, Tat, and the transactivation response element (TAR) are disrupted by a cysteine to tyrosine substitution found in mouse cyclin T. Proc Natl Acad Sci U S A 96:1285–1290[CrossRef]
GarberM. E.,
WeiP.,
JonesK. A.1998a; HIV-1 Tat interacts with cyclin T1 to direct the P-TEFb CTD kinase complex to TAR RNA. Cold Spring Harb Symp Quant Biol 63:371–380[CrossRef]
GarberM. E.,
WeiP.,
KewalRamaniV. N.,
MayallT. P.,
HerrmannC. H.,
RiceA. P.,
LittmanD. R.,
JonesK. A.1998b; The interaction between HIV-1 Tat and human cyclin T1 requires zinc and a critical cysteine residue that is not conserved in the murine CycT1 protein. Genes Dev 12:3512–3527[CrossRef]
HerediaA.,
DavisC.,
BambaD.,
LeN.,
GwarzoM. Y.,
SadowskaM.,
GalloR. C.,
RedfieldR. R.2005; Indirubin-3′-monoxime, a derivative of a Chinese antileukemia medicine, inhibits P-TEFb function and HIV-1 replication. AIDS 19:2087–2095[CrossRef]
HerrmannC. H.,
CarrollR. G.,
WeiP.,
JonesK. A.,
RiceA. P.1998; Tat-associated kinase, TAK, activity is regulated by distinct mechanisms in peripheral blood lymphocytes and promonocytic cell lines. J Virol 72:9881–9888
IvanovD.,
KwakY. T.,
NeeE.,
GuoJ.,
Garcia-MartinezL. F.,
GaynorR. B.1999; Cyclin T1 domains involved in complex formation with Tat and TAR RNA are critical for tat -activation. J Mol Biol 288:41–56[CrossRef]
KimY. K.,
BourgeoisC. F.,
IselC.,
ChurcherM. J.,
KarnJ.2002; Phosphorylation of the RNA polymerase II carboxyl-terminal domain by CDK9 is directly responsible for human immunodeficiency virus type 1 Tat-activated transcriptional elongation. Mol Cell Biol 22:4622–4637[CrossRef]
KimY. K.,
BourgeoisC. F.,
PearsonR.,
TyagiM.,
WestM. J.,
WongJ.,
WuS. Y.,
ChiangC. M.,
KarnJ.2006; Recruitment of TFIIH to the HIV LTR is a rate-limiting step in the emergence of HIV from latency. EMBO J 25:3596–3604[CrossRef]
LindK. E.,
DuZ.,
FujinagaK.,
PeterlinB. M.,
JamesT. L.2002; Structure-based computational database screening, in vitro assay, and NMR assessment of compounds that target TAR RNA. Chem Biol 9:185–193[CrossRef]
ManceboH. S.,
LeeG.,
FlygareJ.,
TomassiniJ.,
LuuP.,
ZhuY.,
PengJ.,
BlauC.,
HazudaD.other authors1997; P-TEFb kinase is required for HIV Tat transcriptional activation in vivo and in vitro . Genes Dev 11:2633–2644[CrossRef]
MichelsA. A.,
NguyenV. T.,
FraldiA.,
LabasV.,
EdwardsM.,
BonnetF.,
LaniaL.,
BensaudeO.2003; MAQ1 and 7SK RNA interact with CDK9/cyclin T complexes in a transcription-dependent manner. Mol Cell Biol 23:4859–4869[CrossRef]
NguyenV. T.,
KissT.,
MichelsA. A.,
BensaudeO.2001; 7SK small nuclear RNA binds to and inhibits the activity of CDK9/cyclin T complexes. Nature 414:322–325[CrossRef]
OkamotoH.,
CujecT. P.,
OkamotoM.,
PeterlinB. M.,
BabaM.,
OkamotoT.2000; Inhibition of the RNA-dependent transactivation and replication of human immunodeficiency virus type 1 by a fluoroquinoline derivative K-37. Virology 272:402–408[CrossRef]
SchulteA.,
CzudnochowskiN.,
BarboricM.,
SchonichenA.,
BlazekD.,
PeterlinB. M.,
GeyerM.2005; Identification of a cyclin T-binding domain in Hexim1 and biochemical analysis of its binding competition with HIV-1 Tat. J Biol Chem 280:24968–24977[CrossRef]
TaubeR.,
FujinagaK.,
WimmerJ.,
BarboricM.,
PeterlinB. M.1999; Tat transactivation: a model for the regulation of eukaryotic transcriptional elongation. Virology 264:245–253[CrossRef]